irbesartan brands
17 registered brands containing irbesartan in Tanzania.
Irbesartan
PubChem CID 3749Molecular formula: C25H28N6O
Irbesartan prevents angiotensin II binding to the AT<sub>1</sub> receptor in tissues like vascular smooth muscle and the adrenal gland. Irbesartan and its active metabolite bind the AT<sub>1</sub> receptor with 8500 times more affinity than they bind to the AT<sub>2</sub> receptor. Irbesartan's prevention of angiotensin II binding causes vascular smooth muscle relaxation and prevents the secretion of aldosterone, lowering blood pressure. Angiotensin II would otherwise bind to the AT<sub>1</sub> receptor, inducing vasoconstriction and aldosterone secretion, raising blood pressure. Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system (RAS) and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor. There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity. Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure. Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis. Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.
Source: PubChem (NCBI) · compound 3749
| Product | Manufacturer | Status | Country |
|---|---|---|---|
| Co-Irda Film Coated Tablet |
Nobel Ilaç | Registered/Compliant | Tanzania |
| Co-Irda Film Coated Tablet |
Nobel Ilaç | Registered/Compliant | Tanzania |
| IRBEZYD H 150/12.5 Tablets |
- | Registered/Compliant | Tanzania |
| Irbis HT 300/12.5 Tablets |
Hetero Labs | Registered/Compliant | Tanzania |
| IRBIS 150 Tablets |
Hetero Labs | Registered/Compliant | Tanzania |
| IRBIS 300 Tablets |
Hetero Labs | Registered/Compliant | Tanzania |
| IRBIS-H 150 Tablets |
Hetero Labs | Registered/Compliant | Tanzania |
| Irda 150 mg Film Coated Tablet |
Nobel Ilac | Registered/Compliant | Tanzania |
| Irda 300 mg Film Coated Tablet |
Nobel Ilac | Registered/Compliant | Tanzania |
| IROVASC 150 Oral tablet |
- | Registered/Compliant | Tanzania |
| Irovel 150 mg Tablet Oral tablet |
Sun Pharma | Registered/Compliant | Tanzania |
| Irovel H Oral tablet |
Sun Pharma | Registered/Compliant | Tanzania |
| Irovel Tablets Oral tablet |
Sun Pharma | Registered/Compliant | Tanzania |
| Omcasart I 300 Oral tablet |
Saitech Medicare Pvt. Ltd | Registered/Compliant | Tanzania |
| OMCASART-I 150 Oral tablet |
Acme Laboratories | Registered/Compliant | Tanzania |
| SciProvel Film Coated Tablet |
Macleods Pharmaceuticals Limited | Registered/Compliant | Tanzania |
| SciProvel Film Coated Tablet |
Macleods Pharmaceuticals Limited | Registered/Compliant | Tanzania |